PCM
VTYX

Prelude Capital Management’s Ventyx Biosciences VTYX Stock Holding History

Prelude Capital Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,200
Closed -$65.9K – 1577
2025
Q3 		$65.9K Buy
21,200
+5,500
+35% +$14.6K 0.01% 1091
2025
Q2 		$33.6K Buy
+15,700
New +$25.4K ﹤0.01% 964
2025
Q1 		– Sell
-17,499
Closed -$38.3K – 1556
2024
Q4 		$38.3K Sell
17,499
-3,501
-17% -$7.93K ﹤0.01% 1158
2024
Q3 		$45.8K Buy
21,000
+8,900
+74% +$20.5K ﹤0.01% 1217
2024
Q2 		$28K Sell
12,100
-25,300
-68% -$105K ﹤0.01% 1169
2024
Q1 		$206K Buy
37,400
+9,400
+34% +$43K 0.01% 1097
2023
Q4 		$69.2K Buy
+28,000
New +$266K ﹤0.01% 1055
2023
Q3 		– Sell
-7,746
Closed -$254K – 1371
2023
Q2 		$254K Buy
+7,746
New +$267K 0.02% 722

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's VTYX Position: Q4 2025 in Review

Prelude Capital Management sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 21,200 shares — an estimated $65.9K sold.

Prelude Capital Management first reported a position in VTYX in Q2 2023 and held it in 8 quarters. The position peaked at $254K in Q2 2023. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Prelude Capital Management reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 21,200 Ventyx Biosciences shares in Q4 2025, an estimated $65.9K.
  • Prelude Capital Management first reported a position in Ventyx Biosciences in Q2 2023 and held it in 8 quarters.
  • Prelude Capital Management's Ventyx Biosciences position peaked at $254K in Q2 2023.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.